Bavarian Nordic (OTCMKTS:BVNRY) Reaches New 52-Week High – Should You Buy?

Shares of Bavarian Nordic (OTCMKTS:BVNRY) hit a new 52-week high during trading on Tuesday. The company traded as high as $12.56 and last traded at $12.55, with a volume of 2,394 shares trading hands. The stock had previously closed at $12.43.

Bavarian Nordic Stock Performance

The firm has a market cap of $2.98 billion, a P/E ratio of 12.68 and a beta of 1.25. The firm has a 50 day simple moving average of $11.05 and a 200 day simple moving average of $10.07.

Bavarian Nordic (OTCMKTS:BVNRY) last released its quarterly earnings results on Friday, August 21st. The company reported $0.46 earnings per share for the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%. The firm had revenue of $316.47 million for the quarter.

About Bavarian Nordic

Bavarian Nordic A/S is a Denmark-based biotechnology and vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. The company supplies products to government agencies, public-health organizations, healthcare providers and private-sector customers in markets around the world.

Its best-known product is JYNNEOS, also marketed as IMVANEX in Europe and IMVAMUNE in Canada, a non-replicating smallpox and mpox vaccine. Bavarian Nordic also offers vaccines for travelers and other infectious-disease risks, including products targeting rabies, tick-borne encephalitis, typhoid and cholera, as well as selected pediatric and adult immunization needs.

Founded in 1994 and headquartered in Copenhagen, Bavarian Nordic has expanded from a vaccine research company into an international commercial vaccine manufacturer.